Amarin’s $4 Billion Breakthrough Has Helped Ignite Takeover Speculation

Amarin Corp.’s boom from small-cap drugmaker to an almost $5 billion biotech has Wall Street buzzing about what might be next for the company and its coveted heart medicine.

Amarin’s stock has more than quintupled since paradigm-shifting results on the purified fish oil Vascepa on Sept. 24 solidified the company’s position on sector analysts’ lists of potential takeout targets. The drugmaker has also yet to announce an equity offering, which has added to speculation of a deal because a bigger sales force is needed to market the potential blockbuster medicine.